Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Sort descending Date Submission Received Date Recommendation Issued
Izba travoprost ophthalmic solution Glaucoma and ocular hypertension Reimburse with clinical criteria and/or conditions Complete
Darzalex Daratumumab Multiple Myeloma (second-line) Reimburse with clinical criteria and/or conditions Complete
Besponsa Inotuzumab Ozogamicin Acute Lymphoblastic Leukemia (ALL) Reimburse with clinical criteria and/or conditions Complete
Prevymis letermovir Cytomegalovirus infection, prophylaxis Reimburse with clinical criteria and/or conditions Complete
Siliq brodalumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Vosevi sofosbuvir velpatasvir voxilaprevir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete
Adcetris Brentuximab Vedotin HL at high risk of relapse or progression post-ASCT Reimburse with clinical criteria and/or conditions Complete
Alecensaro Alectinib Anaplastic Lymphoma Kinase-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete
Perjeta-Herceptin Combo Pack Pertuzumab-Trastuzumab Combo Pack Early Breast Cancer Do not reimburse Complete
Erleada Apalutamide non-metastatic castrate resistant prostate cancer (nm-CRPC) Reimburse with clinical criteria and/or conditions Complete